Intimation of Trading approval received for 22,44,000/- equity shares.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dipna Pharmachem has received BSE trading approval for 22.44 lakh fully paid-up equity shares issued to non-promoters on a preferential basis through conversion of previously allotted convertible warrants. The shares carry a face value of Rs. 10 each with a premium of Rs. 3.05, translating to an issue price of Rs. 13.05 per share and a total capital raise of roughly Rs. 2.93 crore. Trading in these shares commenced on the exchange from January 20, 2026, with distinctive share numbers running from 24045251 to 26289250. The in-principle approval for the warrants was received in March 2025, and the listing application was filed in December 2025.
Existing shareholders will see equity dilution of about 22.44 lakh new shares, though the modest size relative to typical small-cap floats means the price impact should be limited. The shares now entering active trading may add some near-term supply pressure, but the capital infusion strengthens the company's equity base.